Commercial Potential of the Forthcoming US Biosimilars Market
|出版商||Frost & Sullivan||商品編碼||296958|
|出版日期||內容資訊||英文 156 Pages
|美國未來的生技仿製藥市場商業性可能性 Commercial Potential of the Forthcoming US Biosimilars Market|
|出版日期: 2014年02月21日||內容資訊: 英文 156 Pages||
本報告基於Frost & Sullivan對美國著名20名專門醫生召開的討論會(2011年10月11∼13日)的討論內容，提供美國的生技仿製藥的處方情形和今後預測之分析、生技仿製藥對今後美國的醫療市場的短期、中期影響考察，並將結果概述為以下內容。
An Addendum to "Specialty Physicians Discuss their Opinions of the United States Biosimilars Market"
Frost & Sullivan assessed physicians' willingness to prescribe biosimilars in the United States. The objective of this research was to conduct a highly qualitative analysis of a representative sample of 20 preselected practicing specialty physicians in the United States in the spirit of an interactive roundtable discussion. The primary goal was to encourage participants to freely express opinions and ideas around all aspects of a topic, facilitating a free exchange about how biosimilars will impact their practice and the overall US healthcare market. The biosimilar research panel was conducted over a three-day period (October 11-13, 2011). Questions and discussions were designed to gauge both short-term and long-term trends and impacts.